The PBM Kickback Prohibition Act would amend ERISA section 408 to ban pharmacy benefit managers from paying kickbacks in connection with services they provide to covered employee benefit plans. It would cover direct and indirect compensation tied to steering business, getting access to a plan, or influencing contracting processes like requests for proposals and market checks. The bill also creates a presumption that payments to brokers, consultants, advisors, or related entities are improper unless there is contemporaneous written proof that the payment reflects fair market value for bona fide services. It would take effect for plan years beginning after enactment.
What This Bill Does
- Bans compensation tied to referrals, renewals, access, or placement of covered plan business for PBM services.
- Covers both direct and indirect compensation paid by a PBM service provider.
- Applies to contracting steps like a request for proposal, market check, evaluation, or any other contracting process.
- Treats payments to brokers, consultants, advisors, or related entities as presumptively improper unless documented otherwise.
- Effective for plan years beginning after the date of enactment.
Who This Bill Affects
For a typical person, this bill would not directly change whether you can get health coverage, but it could affect how employer-sponsored drug plans are negotiated and administered. If the new anti-kickback rules reduce conflicted payments in PBM contracting, some plans could see lower administrative friction or different drug-benefit pricing; if compliance costs rise, employers and plans could adjust premiums or plan design. The effects would be indirect unless you are a worker, employer, broker, consultant, or PBM involved in an ERISA-covered plan.
See how this bill affects you — sign in for a personalized analysisWho Supports & Opposes This
- Employer health plans and plan fiduciaries Supporters can argue that the bill gives them a clearer rule against hidden compensation arrangements that may distort PBM selection and renewal decisions. By focusing on economic substance rather than labels, it aims to make contracting more transparent and easier to police under ERISA.
- Workers and families enrolled in employer drug plans They may support the bill because kickbacks could contribute to higher drug costs, confusing benefit design, or conflicts of interest in choosing PBMs. A stricter prohibition could, in their view, help ensure that plan decisions are made for the plan’s benefit rather than to generate side payments.
- Independent brokers and consultants who avoid contingent payments Some market participants may favor a bright-line rule because it distinguishes bona fide service fees from compensation tied to steering plan business. That could reward providers that document fair market value and reduce pressure to compete with opaque compensation structures.
- Pharmacy benefit managers PBMs may argue the bill is too broad because it reaches both direct and indirect compensation and could capture ordinary commercial arrangements that are not kickbacks. They may also say it creates uncertainty by relying on how a payment is characterized in economic substance rather than contract labels.
- Brokers, consultants, and related service firms These intermediaries may worry that the presumption against payments to brokerage firms, brokers, consultants, advisors, or related entities will chill legitimate consulting and advisory work. They may also view the contemporaneous written documentation requirement as burdensome and litigation-prone.
- Employers sponsoring ERISA health plans Plan sponsors may be concerned that compliance costs and contract renegotiations will rise if existing PBM and consultant payment arrangements must be restructured. They may also fear that fewer compensation options could reduce flexibility in obtaining services or market-check support.
Key Implications
-
““no amount of compensation ... may be paid ... for the referral, recommendation, placement, retention, or renewal of ... the business of the covered plan””
This is the core anti-kickback rule. It means PBM-related payments connected to steering or keeping plan business would be prohibited for ERISA-covered arrangements.
-
““inclusion in, participation in, or the design of ... a request for proposal””
Payments linked to how a PBM is chosen or renewed would be covered, not just payments made after a contract is already in place. That could change how bids and renewals are negotiated.
-
““characterization ... shall be based on the economic substance and practical operation””
Contract labels would not control if the real-world function of a payment is a prohibited kickback. This gives regulators or litigants a broader basis to challenge arrangements that are described one way but operate another way.
-
““presumed to be related ... unless ... contemporaneous written documentation””
Payments to brokers, consultants, advisors, or related entities start with a presumption of impropriety. To overcome it, the parties must have written records showing fair market value and bona fide services actually rendered.
-
““apply for plan years beginning after the date of enactment””
The new rule would not take effect immediately upon signing; it would begin with the next plan year after enactment. That gives employers and service providers time to revise contracts and compliance practices.
Official Source & Bill Facts
BillBoard checks this page against public Congress.gov metadata, then adds plain-English analysis where available.
- Bill
- HR 7895
- Congress
- 119th Congress
- Official title
- PBM Kickback Prohibition Act
- Policy area
- Healthcare
- Latest action
- Placed on the Union Calendar, Calendar No. 634. (July 2, 2026)
- Last updated
- July 3, 2026
Latest Status
July 2, 2026
Placed on the Union Calendar, Calendar No. 634.
Related Bills
Take Action
Get more from BillBoard
Free tools to understand, respond to, and track this bill.
Ask AI about this billData sourced from api.congress.gov.